Group One Trading’s Arbutus Biopharma ABUS Stock Holding History

Group One Trading’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$823K	Buy	182,900 +134,900	+281%	+$590K	﹤0.01%	2894
2025 Q4	$231K	Buy	48,000 +42,400	+757%	+$191K	﹤0.01%	4248
2025 Q3	$25.4K	Sell	5,600 -900	-14%	-$3.31K	﹤0.01%	6521
2025 Q2	$20.1K	Sell	6,500 -13,500	-68%	-$44.8K	﹤0.01%	6262
2025 Q1	$69.8K	Sell	20,000 -900	-4%	-$3K	﹤0.01%	4897
2024 Q4	$68.3K	Buy	20,900 +400	+2%	+$1.47K	﹤0.01%	4821
2024 Q3	$78.9K	Sell	20,500 -3,400	-14%	-$13K	﹤0.01%	4354
2024 Q2	$73.9K	Buy	23,900 +3,800	+19%	+$11.4K	﹤0.01%	4213
2024 Q1	$51.9K	Sell	20,100 -243,500	-92%	-$631K	﹤0.01%	4684
2023 Q4	$659K	Buy	263,600 +248,500	+1,646%	+$487K	﹤0.01%	2836
2023 Q3	$30.7K	Sell	15,100 -19,800	-57%	-$41.5K	﹤0.01%	5526
2023 Q2	$80.3K	Buy	34,900 +17,700	+103%	+$46.1K	﹤0.01%	4837
2023 Q1	$52.1K	Sell	17,200 -4,200	-20%	-$11.8K	﹤0.01%	4812
2022 Q4	$49.9K	Sell	21,400 -6,100	-22%	-$14.6K	﹤0.01%	4993
2022 Q3	$53K	Sell	27,500 -16,300	-37%	-$38.4K	﹤0.01%	5354
2022 Q2	$119K	Sell	43,800 -191,900	-81%	-$491K	﹤0.01%	4812
2022 Q1	$702K	Sell	235,700 -119,600	-34%	-$366K	﹤0.01%	3457
2021 Q4	$1.38M	Buy	355,300 +48,300	+16%	+$188K	﹤0.01%	3002
2021 Q3	$1.32M	Sell	307,000 -110,800	-27%	-$369K	﹤0.01%	3109
2021 Q2	$1.27M	Buy	417,800 +282,500	+209%	+$875K	﹤0.01%	3134
2021 Q1	$451K	Sell	135,300 -62,900	-32%	-$243K	﹤0.01%	4165
2020 Q4	$704K	Buy	198,200 +144,400	+268%	+$506K	﹤0.01%	2960
2020 Q3	$168K	Buy	53,800 +51,300	+2,052%	+$156K	﹤0.01%	3804
2020 Q2	$5K	Sell	2,500 -8,200	-77%	-$13.4K	﹤0.01%	5344
2020 Q1	$11K	Buy	+10,700	New	+$28.9K	﹤0.01%	4511
2019 Q4	–	Sell	-4,000	Closed	-$6K	–	5040
2019 Q3	$6K	Hold	4,000	–	–	﹤0.01%	4708
2019 Q2	$8K	Buy	+4,000	New	+$10.2K	﹤0.01%	4477
2019 Q1	–	Sell	-5,000	Closed	-$19K	–	4719
2018 Q4	$19K	Buy	+5,000	New	+$24.6K	﹤0.01%	4034
2018 Q3	–	Sell	-22,000	Closed	-$161K	–	5121
2018 Q2	$161K	Buy	22,000 +20,600	+1,471%	+$123K	﹤0.01%	3215
2018 Q1	$7K	Buy	+1,400	New	+$7.41K	﹤0.01%	4408
2017 Q4	–	Sell	-16,200	Closed	-$100K	–	4782
2017 Q3	$100K	Sell	16,200 -8,700	-35%	-$37.2K	﹤0.01%	3244
2017 Q2	$90K	Buy	24,900 +1,000	+4%	+$3.44K	﹤0.01%	3181
2017 Q1	$78K	Sell	23,900 -97,600	-80%	-$271K	﹤0.01%	3129
2016 Q4	$298K	Buy	121,500 +73,600	+154%	+$214K	﹤0.01%	2134
2016 Q3	$165K	Buy	47,900 +20,600	+75%	+$80.5K	﹤0.01%	2610
2016 Q2	$95K	Buy	27,300 +11,300	+71%	+$47.8K	﹤0.01%	2898
2016 Q1	$66K	Sell	16,000 -2,400	-13%	-$8.57K	﹤0.01%	3104
2015 Q4	$82K	Sell	18,400 -62,000	-77%	-$340K	﹤0.01%	3106
2015 Q3	$490K	Sell	80,400 -7,500	-9%	-$66.5K	0.01%	1801
2015 Q2	$1.04M	Buy	87,900 +22,900	+35%	+$348K	0.01%	1170
2015 Q1	$1.14M	Buy	65,000 +8,100	+14%	+$166K	0.02%	973
2014 Q4	$862K	Sell	56,900 -8,900	-14%	-$154K	0.01%	1161
2014 Q3	$1.39M	Buy	65,800 +31,100	+90%	+$508K	0.02%	897
2014 Q2	$453K	Sell	34,700 -23,500	-40%	-$333K	0.01%	1724
2014 Q1	$1.25M	Buy	+58,200	New	+$1.05M	0.02%	919

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Group One Trading's ABUS Position: Q1 2026 in Review

Group One Trading reduced its Arbutus Biopharma (ABUS) stake by 13% in Q1 2026, selling an estimated $33.1K and leaving 50,843 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

Group One Trading first reported a position in ABUS in Q1 2014 and has held it in 36 quarters since. The position peaked at $1.4M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Group One Trading held 50,843 shares of Arbutus Biopharma worth $229K as of Q1 2026.
Group One Trading sold 7,573 Arbutus Biopharma shares in Q1 2026, an estimated $33.1K.
Arbutus Biopharma made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4003 holding.
Group One Trading first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 36 quarters since.
Group One Trading's Arbutus Biopharma position peaked at $1.4M in Q4 2021.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.